Is NWPHF or DIVO a better dividend investment in 2026?

NWPHF currently yields 16.67% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: NWPHF offers higher current income.

What is the dividend yield difference between NWPHF and DIVO?

NWPHF has a forward dividend yield of 16.67% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 10.18 percentage points.

Home › Compare › NWPHF vs DIVO

NWPHF vs DIVO: Dividend Comparison 2026

NWPHF yields 16.67% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NWPHF wins by $28.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

NWPHF

● Live price

16.67%

Share price

$12.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$59.4K

Annual income

$4,638.76

Full NWPHF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — NWPHF vs DIVO

📍 NWPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NWPHF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NWPHF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NWPHF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NWPHF

Annual income on $10K today (after 15% tax)

$1,416.67/yr

After 10yr DRIP, annual income (after tax)

$3,942.95/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, NWPHF beats the other by $3,108.52/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NWPHF + DIVO for your $10,000?

NWPHF: 50%DIVO: 50%

100% DIVO50/50100% NWPHF

Portfolio after 10yr

$45.1K

Annual income

$2,810.22/yr

Blended yield

6.24%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NWPHF buys

DIVO buys

No recent congressional trades found for NWPHF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNWPHFDIVO

Forward yield	16.67% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$59.4K ✓	$30.7K
Annual income after 10y	$4,638.76 ✓	$981.68
Total dividends collected	$30.6K ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: NWPHF vs DIVO ($10,000, DRIP)

Year	NWPHF Portfolio	NWPHF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$12,367	$1,666.67	$11,349	$649.42	+$1.0K → NWPHF
2	$15,159	$1,926.27	$12,833	$688.83	+$2.3K → NWPHF
3	$18,426	$2,206.69	$14,459	$727.90	+$4.0K → NWPHF
4	$22,223	$2,506.90	$16,238	$766.49	+$6.0K → NWPHF
5	$26,604	$2,825.66	$18,179	$804.47	+$8.4K → NWPHF
6	$31,628	$3,161.43	$20,293	$841.71	+$11.3K → NWPHF
7	$37,355	$3,512.53	$22,591	$878.14	+$14.8K → NWPHF
8	$43,847	$3,877.10	$25,087	$913.65	+$18.8K → NWPHF
9	$51,169	$4,253.19	$27,791	$948.18	+$23.4K → NWPHF
10	$59,390	$4,638.76	$30,718	$981.68	+$28.7K → NWPHF

NWPHF vs DIVO: Complete Analysis 2026

NWPHF — Stock

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Full NWPHF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this NWPHF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NWPHF vs SCHD NWPHF vs JEPI NWPHF vs O NWPHF vs KO NWPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.